Surgical Margin Width Is a Reasonable Surrogate for Van Nuys Prognostic Index

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

LOS ANGELES-Surgical margin width offers a reasonable prognostic surrogate for the more complicated multiparameter Van Nuys Prognostic Index to predict breast cancer recurrence after treatment for ductal carcinoma in situ (DCIS), but the index still provides superior accuracy, Melvin J. Silverstein, MD, of the University of Southern California, said at the San Antonio Breast Cancer Symposium.

LOS ANGELES—Surgical margin width offers a reasonable prognostic surrogate for the more complicated multiparameter Van Nuys Prognostic Index to predict breast cancer recurrence after treatment for ductal carcinoma in situ (DCIS), but the index still provides superior accuracy, Melvin J. Silverstein, MD, of the University of Southern California, said at the San Antonio Breast Cancer Symposium.

He said that the index “should be superior because it incorporates four factors (tumor size, biologic classification based on tumor grade and necrosis, and excision margin width), but it is clearly more difficult to use.”

In 1999, Dr. Silverstein and his colleagues published a paper advocating the use of margin width as the sole determinant of treatment for DCIS (N Engl J Med 340:1455-1461, 1999). Afterwards, the group was “inundated with questions about whether to abandon the Van Nuys Prognostic Index,” Dr. Silverstein said. This led the researchers to compare the prognostic value of the index vs surgical margins alone in DCIS patients.

Recurrence-Free Survival

A surgical margin of greater than 10 mm was associated with a 12-year recurrence-free survival of 96%, compared with 99% for patients with a score of 3-4 (the best possible score) on the index. The difference did not achieve statistical significance but showed a trend in favor of the index.

The data came from an evaluation of 523 DCIS patients treated by breast-conserving surgery (with or without radiation therapy). A total of 88 local recurrences have been documented, 41 invasive cancers and 47 DCIS recurrences. All but seven recurrences were at or near the site of the primary lesion, suggesting inadequate surgery, he said.

There was a single recurrence of DCIS associated with an index score of 3-4. Five recurrences were observed in patients who had wide margins, but two recurrences were invasive and one patient had metastatic disease and subsequently died. At the other end of the spectrum, an index score of 8 or 9 was associated with poorer outcomes than was the single prognostic factor of narrow surgical margins.

Dr. Silverstein stressed that the index remains the preferred method at his institution. The best possible score on the index is 3 (low biologic classification, small size, wide margins), while the worst is 9 (large, poorly excised tumor with a high biologic classification). His analyses have shown that DCIS patients with a score of 3-4 derive no benefit from radiation therapy; a score of 5-7 is associated with a 15% benefit from radiation therapy, and a score of 8-9 with a 30% benefit.

His group recommends excision alone for DCIS patients with scores of 3-4, excision plus irradiation for those with scores of 5-7, and mastectomy for patients with scores of 8-9.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.